CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
GSK2190915 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00812929
NCT00812929Phase 2Completed
CompareCT.gov

A Multi-centre, Randomized, Double-blind, Five-way Crossover Study Evaluating the Dose Response and Duration of Action of GSK2190915 Compared to Placebo in Subjects With Mild Asthma Who Experience Exercise Induced Bronchoconstriction.

GlaxoSmithKline·interventional·Posted Dec 22, 2008·Updated Sep 19, 2017

In Brief

A Phase 2 clinical trial evaluating Placebo and GSK2190915 for Asthma. Completed, enrolled 47 participants across 6 sites.

Detailed Summary

This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 22, 2008
Enrollment StartDec 1, 2008
Primary CompletionJun 1, 2009
Study CompletionJul 15, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.5 years ago

Interventions

Placebodrug

The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.

GSK2190915drug

This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.